News | April 20, 2026
Pharma stocks face Q4 reality check amid global headwinds
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
Subscribe To Our Newsletter & Stay Updated
